Open AccessSecukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study
Author(s) -
Ramesh M Bhat,
B Leelavathy,
Sacchidanand Sarvajnamurthy Aradhya,
MG Gopal,
D. V. S. Pratap,
Mir Mubashir,
Putta Srinivas,
Sushil Pande,
Amit S Thavkar
Publication year - 2017
Publication title -
indian dermatology online journal
Language(s) - English
Resource type - Journals
eISSN - 2249-5673
pISSN - 2229-5178
DOI - 10.4103/2229-5178.198765
Subject(s) - secukinumab , medicine , placebo , psoriasis area and severity index , etanercept , psoriasis , tolerability , randomized controlled trial , interleukin 17 , adverse effect , dermatology , psoriatic arthritis , cytokine , pathology , tumor necrosis factor alpha , alternative medicine
Secukinumab efficacy and safety in Indian patients with moderate-to-severe plaque psoriasis: sub-analysis from FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), a randomized, placebo-controlled, phase 3 study.